Browse every published article, from the latest research to earlier analysis. Use the page numbers below to explore the complete archive.
A systematic review found an association between prescribed benzodiazepines and suicidal behaviors, while leaving causal direction and individual attribution unresolved.
A small randomized trial showed that a physiological endpoint and a clinical behavioral endpoint need not improve together.
A receptor study demonstrated substantial pharmacological diversity among prescription and designer benzodiazepines, without directly ranking their clinical toxicity.
A randomized comparison favored midazolam for achieving a deliberately deep sedation target, while dexmedetomidine had fewer hypotension events.
A Dutch registry study identified factors associated with new benzodiazepine–opioid dispensing overlap after elective joint replacement.
A randomized trial reported less shivering with remimazolam after fetal delivery, without establishing a sedation-independent mechanism.
An administrative study associated prior benzodiazepine use with more postoperative opioid dispensing in previously opioid-naive patients.
A Chinese epilepsy cohort reported favorable seizure outcomes after adjunctive clobazam, but its changing response percentages require a longitudinal interpretation.
A hospital study found that nonmedical prescription-drug access often involved relatives or acquaintances, rather than a single illicit-market route.
A registry study found that starting automated multi-dose dispensing often coincided with changes in psychotropic use rather than a stable medication baseline.
A severe dementia case demonstrates that catatonic features do not guarantee a benzodiazepine response.
A cohort study found different prescribing patterns among nurse practitioners who obtained a historical buprenorphine waiver, without isolating the effect of training.
A primary-care cohort associated greater continuity with fewer selected prescribing concerns, including benzodiazepines in patients at risk of falls.
A neonatal case reports survival and improvement during treatment that combined spasm control with several other interventions.
A prolonged neurotoxicity case illustrates why improvement in an EEG after lorazepam does not establish removal of the underlying cause.
A systematic review found promising symptom findings while emphasizing that the evidence did not establish one standardized treatment protocol.
A hospital protocol evaluation reported a favorable adherence subgroup without establishing an overall improvement in its main comparison.
A neuroscience experiment shows that medicines grouped as sleep aids can have different effects on the same brain signal.
A Swedish study found that duration of nursing-home residence did not uniformly explain potentially inappropriate prescribing.
A veterinary series described medication responses in dogs with confirmed standing-related tremor, but it could not establish comparative treatment effectiveness.
A computational metabolism study generated a hypothesis about lorazepam binding without demonstrating enzymatic metabolism.
A community-pharmacy survey found long treatment histories and practical opportunities for support, but many participants were not ready to discontinue medication.
A regional Spanish study describes neonatal abstinence diagnoses, while its drug-attribution discussion requires caution in mixed exposures.
A preclinical adjunct study illustrates why improvement in tissue markers should not be equated with recovery of tested behavior.
A randomized veterinary trial cannot isolate a diazepam effect when both comparison groups received it.
A qualitative component of a benzodiazepine-reduction program explains implementation variation without proving which component caused reduced prescribing.
A community-pharmacy surveillance project identified benzodiazepines frequently among flagged requests, with important classification limits.
A study of methadone take-home changes cautions against attributing every pandemic-period drug-test change to the policy itself.
A diabetic-neuropathy experiment examined a non-benzodiazepine anxiolytic, so its findings cannot be assigned to the benzodiazepine class.
A pharmacovigilance analysis found different reporting patterns across hypnotics, but it cannot determine how often users develop misuse or dependence.